- The
1980s gave birth to the notion that opioids could be widely prescribed as
non-addictive and quality-of-life enhancing drugs
- Therma
Bright is testing its trademarked infrared heat therapy with cannabidiol
to combat general and chronic pain
- The
company is also making strides in testing a way to combat mosquito-borne
viruses
Media attention to the so-called “opioid crisis” has sparked
a new confluence of research and policy as medical professionals reevaluate
existing prescriber practices for pain medications, advocates drive social
change in drug use perspectives and politicians ponder best legislative
practices for a wide variety of constituents. As non-addictive cannabidiol
(“CBD”) has gained a significant following because of its reputed pain and
spasm therapeutic capabilities, companies such as medical device innovator Therma
Bright Inc. (TSX.V: THRM) (OTC: THRBF) are finding a ready market for their
products.
Therma Bright is making a name for itself by targeting a
variety of topical pain and injury concerns, using thermic heat-generating
infrared light products to target troublesome cells and boost the skin’s
defenses. The company’s trademarked TherOZap technology is currently being
tested as a means of fighting the mosquito-borne Zika virus.
Therma Bright is also preparing to test its thermal
technologies in concert with the non-addictive cannabidiol hemp-derivative in
search of a response to general or chronic pain, such as back pain, arthritic
pain and other orthopedic concerns (http://ibn.fm/FetLz). The company announced that it had
developed its first prototype in December and that it aims to develop a pain
therapy that will use creams, gels or salves.
Concerns about pain medicine and the growing number of
opioid addictions and related deaths have largely been the driver behind the
expanding popularity of cannabis — or medical marijuana — legalization during
the past few years (http://ibn.fm/oXWQB).
A professional response to pain issues was established as a
medical field in the 1960s and, in the 1980s, sparked a societal phenomenon
when several prominent pain specialists suggested that opioid use resulted in a
“low incidence of addictive behavior” and began encouraging increased use of
the drugs to provide a general better quality of life to anyone, according to
the Canadian Medical Association Journal (http://ibn.fm/l6LEj).
“We are in this culture now where too many people see drugs
as the answer not only to pain, but to improving their lives,” Marcia Meldrum,
an associate researcher in the department of psychiatry and biobehavioral
sciences at the University of California, Los Angeles, told the Journal.
“Pain can make it impossible to live your life. You lose so much quality of life.
So for many people, if the solution also means they may become somewhat
dependent on a drug, they probably think, ‘Well, that would be better than
this.’”
Therma Bright’s efforts to develop a non-addictive pain
reliever for common maladies using its natural therapy technology is also an
effort to solve the social crisis surrounding the addictive opioids.
The company got its start in the field of using infrared
light to tackle skin problems by delivering controlled, non-burning heat to
cold sore-afflicted areas. Its InterceptCS product was developed to kill cells
infected with the herpes simplex Type 1 virus well over a decade ago (http://ibn.fm/x0sXy).*
For more information, visit the company’s website at www.ThermaBright.com
* Based on double blind placebo study the InterceptCS is
approved for the claim “For prevention of cold sores when used within 3 hours
of the onset of the prodrome” by Health Canada. The InterceptCS is not approved
by the United States FDA for any claim of clinical indication, clinical
efficacy and/or cure or prevention of disease.
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment